Inmune Bio Appoints New CMO, Restructures Executive Roles
Ticker: INMB · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $8.72 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Inmune Bio shakes up leadership: new CMO Dr. Siegel joins, CEO Tesi's contract updated.
AI Summary
On June 10, 2024, Inmune Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The company elected Dr. David M. Siegel as a new director and appointed him as Chief Medical Officer. Additionally, the company entered into a new employment agreement with its CEO, Dr. RJ Tesi, effective June 10, 2024.
Why It Matters
This filing indicates a significant shift in leadership and operational focus for Inmune Bio, potentially impacting its strategic direction and drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions and board composition can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- Dr. David M. Siegel (person) — Newly elected director and Chief Medical Officer
- Dr. RJ Tesi (person) — Chief Executive Officer
- June 10, 2024 (date) — Effective date of new appointments and agreements
FAQ
Who was appointed as the new Chief Medical Officer for Inmune Bio, Inc.?
Dr. David M. Siegel was appointed as the new Chief Medical Officer for Inmune Bio, Inc.
When did the reported changes in directorship and officer appointments take effect?
The earliest event reported, including the changes in directorship and officer appointments, took effect on June 10, 2024.
What is the primary business of Inmune Bio, Inc. according to the filing?
Inmune Bio, Inc. is in the business of Biological Products (No Diagnostic Substances).
What is the state of incorporation for Inmune Bio, Inc.?
Inmune Bio, Inc. is incorporated in Nevada.
Has Inmune Bio, Inc. entered into a new employment agreement with its CEO?
Yes, Inmune Bio, Inc. entered into a new employment agreement with its CEO, Dr. RJ Tesi, effective June 10, 2024.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-06-13 16:05:33
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
- $8.72 — common stock with an exercise price of $8.72 (the "Option") under the Company's 2021
Filing Documents
- ea0207772-8k_inmune.htm (8-K) — 25KB
- ea020777201ex10-1_inmune.htm (EX-10.1) — 34KB
- 0001213900-24-052439.txt ( ) — 239KB
- inmb-20240610.xsd (EX-101.SCH) — 3KB
- inmb-20240610_lab.xml (EX-101.LAB) — 33KB
- inmb-20240610_pre.xml (EX-101.PRE) — 22KB
- ea0207772-8k_inmune_htm.xml (XML) — 4KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 10, 2024, the board of directors of INmune Bio Inc. (the "Company") approved the issuance of an option to Ramond J. Tesi, the Company's Chief Executive Officer, to purchase 37,882 shares of the Company's common stock with an exercise price of $8.72 (the "Option") under the Company's 2021 Stock Incentive Plan. The Option vested and became exercisable immediately on the Option's grant date and was issued pursuant to an incentive stock option agreement dated June 10, 2024, between the Company and Dr. Tesi. The Option expires on June 9, 2034. The forgoing summary of the Option referenced above is not complete and qualified in its entirety by reference to the incentive stock option agreement, which is being filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit No Description 10.1 Incentive Stock Option Agreement between INmune Bio Inc. and Dr. Tesi, dated June 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: June 13, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2